GlassScriptPhysician profile
Jeffrey A Coffman
NPI 1629180583
$17,660.41
in general payments reported to CMS, 2019-2025
34 companies · $2,143 in 2025
The $2,143 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $1,438 · 2021: $1,916 · 2022: $2,002 · 2023: $2,665 · 2024: $6,153 · 2025: $2,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,925 · Debt Forgiveness: $3,888 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,925.32 |
| Debt Forgiveness | $3,887.62 |
| Education | $147.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $3,901.36 | 2019-2024 | Neurostar Tms Therapy System |
| Abbvie INC. | $2,726.91 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,765.45 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,155.17 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,131.71 | 2020-2025 | Caplyta |
| Alkermes, INC. | $873.61 | 2019-2025 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $586.52 | 2019-2024 | |
| Allergan, INC. | $585.67 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $531.15 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Harmony Biosciences LLC | $511.29 | 2020-2025 | Wakix |
| Janssen Pharmaceuticals, INC | $500.54 | 2019-2025 | Invega Sustenna, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $468.82 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $428.87 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $381.33 | 2019-2022 | |
| Axsome Therapeutics, INC. | $322.45 | 2022-2025 | Auvelity, Sunosi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $286.22 | 2019-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $231.62 | 2019-2023 | Wellbutrin, Aplenzin |
| Idorsia Pharmaceuticals US INC | $223.26 | 2023-2025 | Quviviq, Quviviq |
| Acadia Pharmaceuticals INC | $167.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $149.21 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $105.58 | 2020-2023 | Belsomra |
| Supernus Pharmaceuticals, INC. | $102.59 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $93.70 | 2019-2021 | |
| Neos Therapeutics, LP | $81.06 | 2020-2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $54.41 | 2023-2024 | Xelstrym, Secuado |
| Indivior INC. | $49.86 | 2022-2024 | Perseris |
| Biogen, INC. | $46.06 | 2025 | Zurzuvae |
| Avanir Pharmaceuticals, INC. | $40.99 | 2020-2021 | |
| Shire North American Group INC | $39.13 | 2019 | |
| Itamar Medical INC | $36.38 | 2024 | Watchpatone |
| Brainsway USA INC | $28.08 | 2022 | |
| Noven Pharmaceuticals, INC. | $19.39 | 2024 | Xelstrym |
| Livanova USA, INC. | $18.20 | 2022 | |
| Eisai INC. | $16.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Coffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.